Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026)
Neurogene's (NGNE) quarterly Depreciation & Amortization (CF) came in at $800000.0 in Q1 2026, up 6.81% YoY from $749000.0 in Q1 2025, and up 9.14% on a QoQ basis from $733000.0 in Q4 2025.
Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $800000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.81% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (changed 0.19% YoY) and the FY2025 annual result came in at $3.0 million, down 6.25% from the prior year.
- Depreciation & Amortization (CF) climbed to $800000.0 in Q1 2026, from $733000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q4 2022 to a low of $323000.0 in Q3 2022.
- A 5-year average of $798352.9 and a median of $800000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 414.62% — and 2023, when it tumbled 55.16%.
- Tracing NGNE's Depreciation & Amortization (CF) over 5 years: stood at $2.0 million in 2022, then plunged by 55.16% to $900000.0 in 2023, then declined by 12.22% to $790000.0 in 2024, then slipped by 7.22% to $733000.0 in 2025, then gained by 9.14% to $800000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $800000.0 (Q1 2026), $733000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 800,000.00 |
| Jun 30, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |